MannKind (MNKD) announced today that Afrezza has received approval from ANVISA. The long-awaited approval is now in the books, and investors are trying to determine exactly how big this news is. The reaction from the market has been muted thus far, and likely for good reason. The press release issued by MannKind had a key phrase that shows further steps are needed before diabetics in Brazil will be inhaling their insulin:
...subject to the pricing registration process by Câmara de Regulação do Mercado de Medicamentos (CMED).
The healthcare system in Brazil is